Lenalidomide Versus Investigator's Choice in Relapsed or Refractory Mantle Cell Lymphoma (MCL-002; SPRINT): a Phase 2, Randomised, Multicentre Trial.
Marek Trneny,Thierry Lamy,Jan Walewski,David Belada,Jiri Mayer,John Radford,Wojciech Jurczak,Franck Morschhauser,Julia Alexeeva,Simon Rule,Boris Afanasyev,Kamil Kaplanov,Antoine Thyss,Alexej Kuzmin,Sergey Voloshin,Kazimierz Kuliczkowski,Agnieszka Giza,Noel Milpied,Caterina Stelitano,Reinhard Marks,Lorenz Truemper,Tsvetan Biyukov,Meera Patturajan,Marie-Laure Casadebaig Bravo,Luca Arcaini The Lancet Oncology（2016）
AI 理解论文
溯源树
样例
